Chapter 7 · Module 9

Hypertension in Pregnancy

Classification, safe pharmacotherapy, acute management, and magnesium sulfate monitoring

Classification of Hypertensive Disorders of Pregnancy

Four Categories — Each with Distinct Risk Profile and Management

Quick Reference: Hypertensive Disorders of Pregnancy

Disorder	Onset / Definition	Key Features	Management Highlights
Chronic hypertension	Before 20 weeks or predates pregnancy; BP at or above 140/90	Affects 1–5% of pregnancies; 20–25% risk of superimposed preeclampsia; BP may fall in 2nd trimester masking disease	Switch to pregnancy-safe agents immediately; treat when BP at or above 140/90 (CHAP trial); target SBP 120–159, DBP 80–104
Gestational hypertension	At or after 20 weeks; no proteinuria or severe features	6% of pregnancies; resolves within 12 weeks postpartum; 15–25% risk of progressing to preeclampsia; ~50% develop chronic HTN within 10 years	Treat severe-range BP; monitor closely for preeclampsia features
Preeclampsia	At or after 20 weeks; BP at or above 140/90 plus at least one severe feature (proteinuria no longer required)	Caused by abnormal placentation → placental ischemia → anti-angiogenic factors (sFlt-1) → systemic endothelial dysfunction; severe features: SBP at or above 160 or DBP at or above 110, thrombocytopenia, creatinine above 1.1, transaminases above 2x ULN, pulmonary edema, headache unresponsive to acetaminophen	Antihypertensives for BP control; magnesium sulfate for seizure prophylaxis in severe disease; delivery is definitive treatment
HELLP syndrome	Severe preeclampsia variant; BP may be only mildly elevated or normal in 15–20% of cases	Hemolysis (elevated LDH, schistocytes); Elevated Liver enzymes (AST/ALT above 2x ULN); Low Platelets (below 100,000; severe below 50,000)	Delivery; corticosteroids for fetal lung maturity if below 34 weeks; magnesium sulfate; antihypertensives
Eclampsia	Grand mal seizure in patient with preeclampsia; antepartum, intrapartum, or postpartum (up to 4 weeks)	Magnesium sulfate: treatment AND prophylaxis; is NOT an antihypertensive — antihypertensive therapy must continue in parallel	Magnesium sulfate loading 4–6 g IV; antihypertensives for BP; delivery is definitive

Antihypertensive Agents in Pregnancy — Safe vs Contraindicated

First-Line Oral Agents (CHAP-Supported)

Safe Antihypertensives in Pregnancy

Labetalol (oral): 100–400 mg two to three times daily; combined alpha/beta blockade — no reflex tachycardia; dual oral and IV utility; monitor neonate for bradycardia and hypoglycemia; avoid in asthma
Nifedipine long-acting (oral only): 30–90 mg once daily; extended-release only — sublingual immediate-release is contraindicated (precipitous BP drop); enhanced hypotension with concurrent magnesium sulfate
Methyldopa (oral): 250–500 mg two to three times daily; longest safety record in pregnancy — 7-year child development follow-up data; most common adverse effect is sedation; positive Coombs test in up to 20%
Hydralazine (oral or IV): oral second-line; IV used for acute severe hypertension; less predictable onset than labetalol or nifedipine; third-line for acute management
Breastfeeding: labetalol, nifedipine, methyldopa, captopril, and enalapril (full-term neonates only) are compatible; ARBs and spironolactone generally avoided

Absolutely Contraindicated — All Trimesters

Agents That Harm the Fetus

ACE inhibitors and ARBs — ABSOLUTE CONTRAINDICATION: fetal kidneys depend on angiotensin II for normal development; blockade causes fetal renal dysgenesis, severe oligohydramnios (can cause fetal demise), pulmonary hypoplasia, limb contractures, neonatal renal failure, calvarial hypoplasia; FDA black box warning — discontinue immediately on confirmed pregnancy
Direct renin inhibitors (aliskiren): same contraindication as ACEi and ARBs
Sodium nitroprusside: releases cyanide ions; fetal liver has limited cyanide metabolism capacity — avoid unless no other option
Mineralocorticoid receptor antagonists: spironolactone, eplerenone, finerenone — generally avoided; anti-androgenic effects and insufficient human safety data
Sublingual immediate-release nifedipine: not the drug itself but the route — causes precipitous uncontrolled hypotension and fetal distress; use oral swallowed formulation only

Acute Severe Hypertension in Pregnancy — Three Agents

Systolic at or above 160 or Diastolic at or above 110 mm Hg — Treat Within 30–60 Minutes

Parenteral and Acute Oral Protocols

Agent / Route	Dosing Protocol	Key Notes
Labetalol IV (first-line)	20 mg IV over 2 min; then 40 mg after 10 min if inadequate; then 80 mg every 10 min; maximum 300 mg per episode; onset 5–10 min	No reflex tachycardia; titratable; extensive obstetric experience; avoid if asthma, bradycardia, or decompensated heart failure; monitor: do not allow HR below 60 bpm or fetal heart rate changes
Nifedipine oral (first-line)	10 mg immediate-release, swallowed (NOT sublingual); repeat in 20–30 min if still severe; maximum 30 mg per episode; onset 20–30 min	Must be swallowed — sublingual route is contraindicated; enhanced hypotension with concurrent magnesium sulfate; monitor BP closely at 20–30 min intervals
Hydralazine IV (third-line)	5–10 mg IV bolus; repeat every 20–30 min; maximum 20 mg per episode; onset variable (10–30 min)	Less predictable response; reflex tachycardia; more adverse effects (headache, flushing, palpitations); use when labetalol and nifedipine are unavailable or contraindicated

Magnesium Sulfate — Dosing, Therapeutic Window & Toxicity Monitoring

Seizure Prophylaxis Only — NOT an Antihypertensive — Antihypertensives Must Continue in Parallel

Loading 4–6 g IV over 15–20 min → Maintenance 1–2 g/hr → Continue 24–48 hr Postpartum

Therapeutic
4–7 mEq/L

Anticonvulsant effect — goal range

Monitor: deep tendon reflexes (patellar) hourly; respiratory rate (maintain at or above 12/min); urine output (maintain at or above 25 mL/hr — magnesium is renally excreted)

Loss of DTRs
7–10 mEq/L

Earliest clinical sign of toxicity — loss of patellar reflex

Reduce infusion rate; re-check magnesium level; increase monitoring frequency

Respiratory Depression
10–13 mEq/L

Respiratory arrest risk — stop infusion immediately

Stop infusion; give antidote: calcium gluconate 1 g IV (10 mL of 10% solution) over 3 minutes — reverses respiratory depression and cardiac toxicity

Cardiac Arrest
Above 15 mEq/L

Cardiac conduction block and arrest

Stop infusion immediately; calcium gluconate antidote; resuscitation; avoid in severe renal impairment without dose reduction

Antidote — Calcium Gluconate 1 g IV over 3 Minutes

Always have calcium gluconate at the bedside during magnesium sulfate infusion. Calcium directly antagonizes magnesium's effects on neuromuscular transmission and cardiac conduction. Dose: 1 g IV (10 mL of 10% calcium gluconate solution) over 3 minutes. Repeat if needed.